Has Marina Russo, MD received payments from drug or device companies?

Yes. Drug and device makers reported $220,236 in general payments to Marina Russo, MD across 333 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marina Russo, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marina Russo, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marina Russo, MD

Endocrinology, Diabetes & Metabolism · Springfield, ILNPI 1174510978

Payments from drug & device makers

$220,236in general payments, 2019–2025

Across 333 payments — averaging $661.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$199K
AstraZeneca$12K
Dompe Farmaceutici S.p.a.$3K
Medtronic$2K
Novo Nordisk$674
Amgen$453
plus $4K from 40 others

$323in research payments, 2019–2025

Across 1 payment — averaging $323.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$323

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	5	$198,703
AstraZeneca(2 entities)	66	$11,821
Dompe Farmaceutici S.p.a.	1	$3,000
Medtronic(2 entities)	17	$1,639
Novo Nordisk	30	$674
Amgen(2 entities)	20	$453
Lilly USA, LLC	25	$443
Boehringer Ingelheim	21	$380
Insulet Corporation	8	$339
AbbVie	11	$233
Abbott	13	$230
Xeris Pharmaceuticals, Inc.	12	$228
Mannkind Corporation	10	$203
Sanofi-aventis U.S. LLC	10	$198
Bayer	5	$173
Novartis	7	$152
Radius Health, Inc.	7	$126
Corcept Therapeutics	5	$119
Recordati_rare_diseases_inc.	4	$109
Johnson & Johnson	6	$104
Merck	8	$102
Esperion Therapeutics, Inc.	5	$86
Neurocrine Biosciences, Inc.	4	$72
Sandoz	3	$63
Sequel Med Tech, LLC	2	$55
Mallinckrodt Hospital Products Inc.	2	$48
BETA Bionics, Inc.	2	$48
Ascendis Pharma Endocrinology Inc	2	$43
Tandem Diabetes Care, Inc.	2	$42
Amneal Pharmaceuticals LLC	2	$41
Amphastar Pharmaceuticals, Inc.	2	$35
Ascensia Diabetes Care US Inc.	1	$29
3b Medical, Inc.	1	$28
Mylan Specialty L.p.	1	$24
Kyowa Kirin, Inc.	1	$20
Electromed, Inc.	1	$19
Rhythm Pharmaceuticals, Inc.	1	$19
Acadia Pharmaceuticals Inc	1	$17
Shire North American Group Inc	1	$16
Actelion Pharmaceuticals US, Inc.	1	$16
Ultragenyx Pharmaceutical Inc.	1	$16
Lifescan, Inc.	1	$15
Argenx US, Inc.	1	$15
Ironwood Pharmaceuticals, Inc	1	$15
Cequr Corporation	2	$12
Dexcom, Inc.	1	$12

How this compares

$220,236 in reported general payments places this provider in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois →

Medicare billing

Part B allowed, 2024

$133,417

Medicare patients

424

Services billed

3,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Springfield

Gabriel UwaifoSpringfield$195K
Kevin HazardSpringfield$44K
Liana BillingsSkokie$3.4M
Leon FogelfeldChicago$1.5M
Grazia AleppoChicago$1.4M
Wahid KassarChicago$884K
Anthony PickLake Forest$665K
Hiralal MaheshwariMcHenry$642K
Wenyu HuangChicago$639K
Babak PazookiJoliet$582K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →